Age: 50-54 55-59 60-64 65-69 70-74 75-79 > 79

1.     Sex: Male Female

2.     Regular Pesticide Exposure: Yes No Not Available
_{(i.e., ≥100 episodes of non-occupational exposure)}

3.     Occupational Solvent Exposure: Yes No Not Available

4.     Consume Caffeinated Bevarage: Yes No Not Available
_{(i.e., <3 cups of coffee/6 cups of black tea per-week)}

5.     Smoking: Never Former Current Not Available

6.     Family History of PD (first degree relative)? Yes No Not Available

7-1   Intermediate Strength Genetic Variants associated with PD
         GBA Mutation (for specific mutation subtypes see: Anheim 2012, Neurology) Yes No Not Available
         LRRK2 (p.G2019S) Mutation (Lee 2017, Mov Disord) Yes No Not Available

7-2   Polygenic Risk Score: High Polygenic Risk Score (i.e.,the highest quartile of scores in a large cohort) Low Polygenic Risk Score (i.e., the lowest quartile of scores in a large cohort) Not Available (or the score falls in between the two quantiles)

8.     Documented Substantia Nigra Hyperechogenicity on Transcranial Ultrasound Yes No Not Available
_{(i.e., SN+ corresponds to an uni- or bilateral hyperechogenic area in the SN (>90^th percentile of the reference sample))}

9.     Medical Diagnosis of Type II Diabetes Mellitus Yes No Not Available

10.   Physical Inactivity: Yes No Not Available
_{(i.e., <1 hour/week of physical activity causing elevating in breath and heart rate/sweating)}

11.    Low Plasma Urate (Men) Yes (in men) No (in men) Not Available

A-1.1 Polysomnograph-proven RBD: Yes No Not Available

A-1.2 Are you able to exclude differential diagnosis when screening for RBD? Yes No
          Results of screeening for RBD: Positive Screen, No Further Confirmation Negative Screen, No Further Confirmation Not Available
_{(*Differential diagnosis and possible drug-induced/nacrolepsy-related dream enactment should be excluded)}

A-2    Excessive Daytime Somnolence: Yes No Not Available
_{(* Possible drug-induced or nacrolepsy-related RBD symptom should be excluded)}

A-3    Olfactory Loss: Yes No Not Available
_{(i.e., total score below age-and-sex-adjusted threshold in a quantitative olfactory test (e.g. Sniffin' Stick, UPSIT or B-SIT)}

A-4    Constipation: Yes No Not Available
_{(i.e., constipation requiring treatment more than once a week, or spontaneous bowel movement frequency less than every other day)}

A-5    Urinary Dysfunction: Yes No Not Available

A-6    Severe Erectile Dysfunction: Yes No Not Available Female Patient

A-7    Has a measurement of orthostatic hypotension been performed at the clinic? Yes No
          Orthostatic Hypotension: OH, with No Alternate Cause on Comprehensive Expert Evaluation OH, Documented, No Further Diagnostic Investigation No OH Diagnosed on Comprehensive Expert Evaluation No Documented OH and Did Not Perform Further Investigation Not Available

A-8    Depression (with/without Anxiety): Yes No Not Available
_{(Clinical diagnosis or reaching thresholds of at least moderate depression in depression inventories/questionnaires)}

A-9    Global Cognitive Deficit: Yes No Not Available
_{(i.e., diagnosed with mild cognitive impairment or score more than 1.5SD below the Age-and-sex-adjusted Norm)}

B-1    UPDRS III Total Score >3 or MDS UPDRS III Total Score >6 (Physician Examination): Yes No Not Available
_{(*Excluding action tremor and potential confounds, such as arthritis)}

B-2    Abnormal Quantitative Motor Testing (i.e., < Mean + 1SD): Yes No Not Available
_{(Abnormalities of quantitative motor tests according to defined thresholds, with performance 1 standard deviation (SD) below age-adjusted normal values. The motor test must be clearly demonstrably abnormal in clinical PD, with specificity compared to controls of ≥80%. If multiple quantitative motor tests are performed, the individual must score below threshold on ≥50% of them. Uncertain or borderline test results should not be included (use evaluator judgment).)}

C-1    Clear Abnormality on Dopaminergic Imaging: Yes No Not Available
_{(e.g., < 65% normal, 2SD below mean)}